ABSTRACT
The adverse effects of 32P are prolonged pancytopenia, which rarely occurs, and a very high risk of leukemia. Indeed, its leukemogenic effect in polycythemia vera has led to the abandonment of 32P as a therapeutic agent in this disorder except in the unusual circumstance where other therapies have failed and life span is limited.
